Author:
Berlin Jordan D.,Rothenberg Mace L.
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Burris HA, III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413. Randomized trial that established gemcitabine activity in pancreatic cancer and was the first to test a new parameter for the clinical effect and clinical benefit response.
2. Tempero M, Plunkett W, Ruiz van Haperen V, et al.: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma [abstract]. Proc ASCO 1999, 18:273a.
3. Maisey, N, Chau I, Cunningham D, et al.: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU)with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002, 20:3130–3136.
4. Ducreux M, Rougier P, Pignon J-P, et al.: A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002, 13:1185–1191.
5. Cartwright TH, Cohn A, Varkey JA, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160–164.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献